Tag: Civitas Therapeutics
Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of its Supervisory Board.
Mr. Iwicki most recently served as President and Chief Executive Officer of biotechnology company Civitas Therapeutics until it was acquired by Acorda Therapeutics in 2014. Previously, Mr. Iwicki was the CEO of Blend Therapeutics and Sunovion Pharmaceuticals.
Mark will replace Gerard van Odijk who has been the company’s President of the Board for the last 7 years.